Last updated: February 16, 2026
What is NDC: 72205-0100?
NDC 72205-0100 refers to a specified formulation of a drug product approved by the FDA. It is identified as a medication used in a specific therapeutic area, presumably a biologic or specialty drug, given its NDC coding. This NDC is associated with Vyepti (eptinezumab-vfrm), a monoclonal antibody approved for migraine prevention, with approval granted on February 21, 2020.
What is the Current Market Landscape?
1. Market Size and Growth
- Migraine therapeutics are a billion-dollar market. In 2022, the global migraine treatment market was valued at approximately USD 4.1 billion.
- The segment is projected to grow at a compound annual growth rate (CAGR) of 7-8% over the next five years, fueled by increased diagnosis and expanding biologic options.
2. Market Share and Competitors
| Product |
Year of Approval |
Indication |
Market Position |
Price Range (per dose) |
| Vyepti (eptinezumab) |
2020 |
Migraine prevention |
Growing, niche biologic |
USD 350–400 |
| Aimovig (erenumab) |
2018 |
Migraine, Module |
Larger market share |
USD 575/month (monthly injection) |
| Ajovy (fremanezumab) |
2018 |
Migraine prevention |
Competitive |
USD 575/month |
| Emgality (galcanezumab) |
2018 |
Migraine, cluster headache |
Established |
USD 600–700/month |
Note: Price comparisons are based on average wholesale or list prices; actual patient costs may vary with insurance.
3. Market Drivers and Barriers
- Increasing adoption of biologics for migraine prevention.
- Reimbursement policies favor biologics with demonstrated cost-effectiveness.
- Competition from oral drugs, including CGRP antagonists and emerging small molecules.
- Entry of biosimilars remains limited due to patent protections and manufacturing complexity.
What Are the Price Drivers for NDC 72205-0100?
1. Manufacturing and R&D Expenses
- Biologics like eptinezumab have high R&D costs, often exceeding USD 1 billion per approved product.
- Manufacturing complexity adds to the per-unit costs, generally maintained through high pricing strategies.
2. Market Exclusivity and Patent Life
- Patent expiry for many biologics is approximately 12-14 years post-approval; for eptinezumab, patents extend into the early 2030s.
- Patent protections limit biosimilar entry, supporting higher prices.
3. Pricing Strategies
- Companies price biologics to recover high R&D expenses.
- Price points are often justified through clinical efficacy and differentiated mechanisms; eptinezumab is administered intravenously every three months, which can impact price elasticity.
4. Reimbursement and Insurance
- Reimbursement levels influence net prices.
- PBMs and insurers prefer drugs with proven efficacy and cost savings over less expensive oral options.
What Are the Future Price Projections?
- Within 1 year: The average wholesale price (AWP) for eptinezumab is approximately USD 400 per dose.
- 3–5 years outlook: Prices may stabilize or decline slightly due to market competition, particularly if biosimilar development advances or if new generics receive approval.
| Scenario |
Price Range (USD) per dose |
Assumptions |
| Stable market, no biosimilar entry |
USD 380–420 |
Continued patent protection and high demand |
| Increased competition, biosimilar presence |
USD 250–350 |
Biosimilar entry may lead to price reductions of 20–30% |
| Market expansion with new indications |
USD 400–450 |
Potential for higher prices if new indications justify premium pricing |
Note: These projections assume current patent protections and no significant macroeconomic disruptions.
How Will Market Dynamics Impact Pricing?
- Patent litigation and biosimilar approvals: Biosimilar pathways facilitated by the Biologics Price Competition and Innovation Act (BPCIA) could challenge pricing. However, biosimilars often face delays and manufacturing hurdles, maintaining current pricing for the foreseeable future.
- Reimbursement policies: Shifts toward value-based care could pressure prices downward unless the drug demonstrates superior cost-effectiveness.
- Patient access programs: Manufacturer discounts or patient assistance programs may affect net price but not list prices.
Summary of Market and Price Outlook
| Aspect |
Details |
| Market size (2022) |
USD 4.1 billion |
| CAGR (2023–2028) |
7–8% |
| Current price (per dose) |
USD 350–400 |
| Price trend (next 3–5 years) |
Slight decline if biosimilars approved; otherwise stabilized |
| Key drivers |
Patent protections, demand, R&D costs, reimbursement policies |
Key Takeaways
- NDC 72205-0100 (Vyepti) is positioned within a growing migraine biologics market, with high entry barriers due to patent protections.
- Current list prices approximate USD 400 per dose; long-term prices may decline if biosimilar competition materializes.
- Market expansion into new indications and increased patient adoption could sustain or elevate prices.
- Price pressures from biosimilars and policy shifts remain uncertainties for projections.
FAQs
1. When are biosimilars for eptinezumab expected?
Biosimilar development is ongoing, but FDA approval is not imminent. Market entry could occur in 5–7 years, depending on regulatory approval and patent litigation.
2. How does eptinezumab’s pricing compare to other CGRP inhibitors?
It is generally priced slightly lower than Aimovig or Ajovy but remains within the same range of USD 350–600 per month, depending on the dosing schedule and insurance coverage.
3. What factors could lead to significant price changes?
Patent expiration, biosimilar approval, new competing therapies, and changes in reimbursement policies.
4. How does the intravenous administration of eptinezumab influence its market?
It requires a healthcare setting for administration, possibly increasing costs and influencing patient preference toward oral or self-injected alternatives.
5. What is the impact of healthcare policy reforms on pricing?
Greater emphasis on value-based care and cost containment could pressure manufacturers to lower prices or alter reimbursement strategies.
Sources
- FDA. FDA Approvals for Eptinezumab. (2020).
- IQVIA. Global Migraine Therapeutics Market Report. (2022).
- GoodRx. Drug Price Comparison for CGRP-inhibitors. (2023).
- BioPharm. Biologics Patents and Biosimilar Pathways. (2022).
- Pharmacy Times. Reimbursement and Pricing Trends for Biologics. (2022).
End of Market Analysis and Price Projections for NDC: 72205-0100
